Insider filing · SION

Ra Capital Management, L.P. bought $20.2M of Sionna Therapeutics (SION)

Executed Feb 10 2025, disclosed Feb 10 2025, the same day.

Over the 21 trading sessions from the disclosed entry session (Feb 10 2025), the stock returned -31.5% (delay-adjusted); from the execution session (Feb 10 2025), -31.5%. Derived: entry at the session's open, exit at the close 20 sessions later.

RP Ra Capital Management, L.P. Director profile →

Ra Capital Management, L.P. (Director) filed 30 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 7 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 23 priced purchase filings, the average 21-session return was +14.9% from execution and +14.0% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.

SION Sionna Therapeutics, Inc. SION · Healthcare · 44 filings in 24 months ticker →

Healthcare · Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibros…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→